Israel - English - Ministry of Health

rafa laboratories ltd - mesalazine - gastro resistant caplets - mesalazine 1000.0 mg - mesalazine - mesalazine - treatment and prevention of ulcerative colitis and crohn's disease.

Israel - English - Ministry of Health

rafa laboratories ltd - mesalazine - suppositories - mesalazine 1000 mg - mesalazine - mesalazine - treatment and prevention of ulcerative colitis and crohn's disease.

Ireland - English - HPRA (Health Products Regulatory Authority)

espl regulatory consulting limited - mesalazine - modified-release tablets - 1600 milligram - aminosalicylic acid and similar agents

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dch auriga (malaysia) sdn. bhd. - 5-amino salicylic acid(5-asa),mesalazine -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dch auriga (malaysia) sdn. bhd. - 5-amino salicylic acid(5-asa),mesalazine -

Canada - English - Health Canada

teva canada limited - mesalazine - tablet (enteric-coated) - 400mg - mesalazine 400mg - anti-inflammatory agents

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - mesalazine, quantity: 250 mg - tablet, enteric coated - excipient ingredients: microcrystalline cellulose; povidone; sodium carbonate; purified talc; titanium dioxide; iron oxide red; colloidal anhydrous silica; calcium stearate; glycine; iron oxide yellow; methacrylic acid copolymer; macrogol 6000; triethyl citrate - indications as at 12 september 1990: treatment of acute inflammatory large bowel disease. maintenance therapy of crohns colitis and ulcerative colitis in patients sensitive to sulfasalazine.

Malta - English - Medicines Authority

espl regulatory consulting ltd - mesalazine - modified-release tablet - mesalazine 1600 milligram(s) - antidiarrheals, intestinal antiinflammatory/antiinfective agents

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - mesalazine, quantity: 1200 mg - tablet, modified release - excipient ingredients: methacrylic acid copolymer; purified talc; silicon dioxide; sodium starch glycollate; stearic acid; iron oxide red; carmellose sodium; carnauba wax; magnesium stearate; titanium dioxide; macrogol 6000; triethyl citrate - for the induction and maintenance of remission in patients with mild to moderate, active ulcerative colitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 3000 mg - granules, modified release - excipient ingredients: aspartame; carmellose sodium; microcrystalline cellulose; citric acid; hypromellose; magnesium stearate; methylcellulose; povidone; colloidal anhydrous silica; simethicone; sorbic acid; purified talc; titanium dioxide; triethyl citrate; methacrylic acid copolymer; flavour - salofalk granules granules are indicated in the treatment of acute ulcerative colitis of mild to moderate severity, and for the maintenance of remission and/or the long term treatment of ulcerative colitis.